



## **Rallybio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference**

September 11, 2020 at 8:00 AM EDT

NEW HAVEN, Conn., September 11, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that Martin Mackay, Co-Founder and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 18<sup>th</sup> Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 4:15 p.m. Eastern Time.

The conference will be held virtually and a live webcast of the event is accessible [here](#). A replay of the webcast will be available in the "Investor" section of Rallybio's [website](#) for approximately 90 days following the conference.

### **About Rallybio**

Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit [www.rallybio.com](http://www.rallybio.com).